门诊阿托瓦斯塔丁的使用和严重的COVID-19结果:基于人口的研究
Irene Visos-Varela1, Maruxa Zapata-Cachafeiro1,2,3, Samuel Pintos-Rodríguez1
1Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Journal of medical virology
|July 24, 2023
概括
慢性阿托瓦斯塔丁使用可能会降低严重的COVID-19结果,包括住院治疗和死亡率. 辛巴斯塔丁也显示死亡风险降低,这表明特定的他类药物,而不是类,影响COVID-19的严重程度.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 关于他类药物的使用和COVID-19的严重程度,存在不一致的证据.
- 类他类药物是常见的降脂药物.
- 了解潜在的保护作用对于患者管理至关重要.
研究的目的:
- 评估慢性他类药物使用与严重的COVID-19结局之间的关联.
- 评估特定的他类药物活性成分对COVID-19风险的影响.
- 调查他类药物对COVID-19住院治疗,死亡率,进展和易感性的影响.
主要方法:
- 基于人口的病例控制研究,使用电子健康记录.
- 评估住院风险,死亡率,进展和对COVID-19的易感性.
- 分析了2821例住院病例,26996例非住院病例和52318例对照病例的数据.
主要成果:
- 慢性阿托瓦斯塔丁使用与COVID-19的住院率 (aOR=0.83) 和死亡率 (aOR=0.70) 的降低有关.
- 阿托瓦斯塔丁的使用也与对病毒的敏感性降低有关 (aOR=0.91).
- 西姆瓦斯塔丁的使用表明死亡风险降低 (aOR=0.59).
- 在他类药物之间显著的异质性表明没有整体类效应.
结论:
- 慢性使用阿托瓦斯塔丁与严重COVID-19结局的风险降低有关.
- 辛巴斯塔丁也可能对COVID-19死亡率提供一些保护.
- 研究结果表明,特定的他类药物,特别是阿托瓦斯塔丁,可能在缓解严重的COVID-19中发挥作用.
- 没有观察到他类药物对COVID-19严重性的整体类效应.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.5K
15:00Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
2.6K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
699
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
699
01:26Coronary Artery Disease IV: Preventive Measures
24
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
24
01:30Acute Coronary Syndrome III: Diagnostic Studies
10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
41
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
41